| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Cypherpunk Technologies Inc.$0.68
+0.02 (+3%)
D 27Pipeline Score Richly Valued Biotech · Clinical
Market Cap
127.76 M
EPS
-0.01
P/E Ratio
-
Value Trade
5.56 M
SEC Financials
Q1 2026Dilution Risk
R&D Expenses
161.00 K
Operating CF
-3.43 M
Total Assets
87.38 M
Total Liabilities
3.00 M
Equity
84.38 M
D/E Ratio
12,345
2.56 %
Week
41.14 %
1 Month
85.5 %
3 Month
-58.48 %
6 Month
-92.59 %
5 Year
-98.04 %
All Time
Cash Data
Cash Position
6.69 M
Monthly Burn
1.14 M
Runway
4.2 mo
Burn Trend
SEC Filing
May 14, 2026
Overview
Volume
1.89 M
52 Week Range
0.23 - 3.70
% held by Insiders
15.13 %
% held by Institutions
6.88 %
Enterprise Value
121.11 M
Total Shares
97.71 M
Short %
7.72 %
Float Shares
65.46 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Cypherpunk Technologies Inc.
296Total events
2Upcoming
61Tier-1 (high impact)
2016 – 2026Coverage
Upcoming catalysts 2
Event history 294
May 2026
▲Fast Track DesignationsirexatamabDesignation
FDA granted Fast Track designation for sirexatamab in combination with chemotherapy and bevacizumab for DKK1-high metastatic colorectal cancer
DKK1-high metastatic colorectal cancersource ↗
Apr 2026
▲Oral PresentationsirexatamabPresentation
Presented new plasma DKK1 biomarker assay and results from Part B of DeFianCe study at AACR 2026
colorectal cancersource ↗
Nov 2025
◆Management ChangeCorporate
Appointed Khing Oei as Chairman of the Board and Will McEvoy as CIO and Board member
Oct 20, 2025
▲Full ResultssirexatamabClinical Data
Final results from Part B of DeFianCe study presented at ESMO 2025
microsatellite stable colorectal cancersource ↗
Oct 20, 2025
●Oral PresentationsirexatamabPresentation
Mini Oral presentation at ESMO Congress 2025
microsatellite stable colorectal cancersource ↗
Oct 20, 2025
Oct 19, 2025
◆Oral PresentationsirexatamabPresentation
Mini Oral Session at ESMO Congress 2025 presenting Phase 2 trial results
colorectal cancersource ↗
Drug Pipeline Intelligence
D27
Pipeline Score $19M
Pipeline ValueRichly Valued
Valuation Signal2
Drugs Scored0.2x
rNPV / MCap Top 28%
Micro Cap (rank 653 of 906)
Percentile RankCypherpunk Technologies Inc. faces pipeline headwinds (27/100), with $617M risk-adjusted pipeline value, led by DKN-01 in Multiple Myeloma (Phase 1), across $51B in total addressable markets, but cash runway is a concern.
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DKN-01 Small molecule | Endometrial Cancer | Phase 2 | NCT05761951 | 19% | $350M | ACTIVE NOT_RECRUITING | 119 | - | - | Jan 31, 2029 | - | LOW May 24, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
sirexatamab Fast Track | colorectal cancer | Phase 2 | 2025-10-20 | statistically significant improvement in PFS and OS; increasing DKK1 levels further improved PFS, OS, and ORR advantage for the Sirexatamab Arm Read More | Leap Therapeutics Presents Final Data from DeFianCe Study at ESMO 2025 Sirexatamab demonstrated statistically significant improvement in PFS and OS in DKK1-high population Increasing DKK1 levels further improved PFS, OS, Read More | |
sirexatamab Fast Track | colorectal cancer | Phase 2 | 2025-10-20 | statistically significant improvement in PFS and OS; increasing DKK1 levels further improved PFS, OS, and ORR advantage for the Sirexatamab Arm Read More | Leap Therapeutics Presents Final Data from DeFianCe Study at ESMO 2025 Sirexatamab demonstrated statistically significant improvement in PFS and OS in DKK1-high population Increasing DKK1 levels further improved PFS, OS, Read More | |
sirexatamab Fast Track | colorectal cancer | Phase 2 | 2025-10-20 | statistically significant improvement in PFS and OS; increasing DKK1 levels further improved PFS, OS, and ORR advantage for the Sirexatamab Arm Read More | Leap Therapeutics Presents Final Data from DeFianCe Study at ESMO 2025 Sirexatamab demonstrated statistically significant improvement in PFS and OS in DKK1-high population Increasing DKK1 levels further improved PFS, OS, Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in CYPH
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
CYPH Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-08-21 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-08-21 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-08-21 | 0.00 | 0 | - | - | - | - | - | - | ||||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
CYPHCypherpunk Technologies Reports First Quarter 2026 Financial Results
Cypherpunk Technologies reported its financial results for Q1 2026, highlighting a significant increase in Zcash holdings and the Fast Track designation for sirexatamab by the FDA. The company faced a net loss of $77.2 million, primarily due to unrealized losses on ZEC holdings. Despite these challenges, Cypherpunk is advancing its privacy technology mission and launched a new investor dashboard.
Read more →CYPHCypherpunk Reports Full Year 2025 Financial Results
Cypherpunk Technologies Inc. reported its financial results for 2025, highlighting a transformational year with a net income of $4.8 million, a significant turnaround from a loss in 2024. The company raised $58.88 million to focus on privacy technologies and made strategic investments in Zcash. Additionally, its subsidiary Leap Therapeutics presented promising data on sirexatamab for colorectal cancer treatment, indicating a positive outlook for future developments.
Read more →CYPHCypherpunk Accelerates Zcash Accumulation; Increa ses Treasury Holdings to 290,062.67 ZEC Cambridge, Mass.
Cypherpunk Technologies Inc. announced an expansion of its treasury by acquiring an additional 56,418.09 ZEC, bringing its total holdings to 290,062.67 ZEC. This acquisition positions the company to accumulate 5% of the Zcash network, reflecting a strategic commitment to privacy-focused technologies. The new additions to their treasury represent a significant investment of approximately $29 million at an average price of $514.02 per ZEC. Additionally, the company plans to continue branching into various privacy-preserving initiatives through its subsidiary Leap Therapeutics.
Read more →CYPHC ypherpunk Purchases Additional $18 Million of ZEC, Bringing Total Network Percentage to 1.43% Cambridge, Mass.
Cypherpunk Technologies Inc. has announced an additional purchase of $18 million worth of ZEC, increasing its total holdings to 233,644.56 ZEC and owning 1.43% of the network. This acquisition follows an earlier purchase of over $50 million in ZEC, reflecting the company's commitment to digital privacy assets. The recent addition of seasoned investors to its Board aims to bolster the company's strategy in both digital asset acquisition and the development of cancer therapies. Overall, Cypherpunk seeks to enhance shareholder value through its diversified focus on privacy and healthcare.
Read more →CYPHLeap Therapeutics Rebrands as Cypherpunk; Expands Leadership Team to Drive New Zcash Treasury Strategy Khing Oei appointed Chairman of the Board; Will McEvoy appointed Chief Investment Officer and Member of the Board; Cy
Leap Therapeutics, now rebranded as Cypherpunk Technologies Inc., is shifting its focus towards accumulating Zcash (ZEC) as part of a new digital asset treasury strategy. The company has announced the acquisition of 203,775.27 ZEC and plans to change its ticker symbol to CYPH. Khing Oei and Will McEvoy have been appointed to the Board of Directors, signaling a commitment to enhancing shareholder value through active participation in the evolving Zcash market. This strategic pivot comes after a successful $58.88 million private placement led by Winklevoss Capital.
Read more →CYPHLeap Therapeutics Presents Final Data from DeFianCe Study at ESMO 2025 Sirexatamab demonstrated statistically significant improvement in PFS and OS in DKK1-high population Increasing DKK1 levels further improved PFS, OS,
Leap Therapeutics announced positive final results from the DeFianCe study, demonstrating that sirexatamab significantly improves progression-free survival (PFS) and overall survival (OS) in colorectal cancer patients with high levels of DKK1. Presented at the ESMO Congress 2025, these findings support the potential of sirexatamab in enhancing treatment options for patients who have limited alternative therapies. The company aims to move forward with a registrational trial and optimize diagnostic testing for DKK1 levels to identify suitable patients. Leap Therapeutics remains focused on developing targeted therapies for complex cancers.
Read more →CYPHLeap Therapeutics Announces Closing of $58.88 Million Private Placement in Cash Led by Winklevoss Capital to Initiate a Digital Asset Treasury Strategy Cambridge, MA
Leap Therapeutics has successfully closed a private placement raising $58.88 million, led by Winklevoss Capital to begin a digital asset treasury strategy. The transaction involves the issuance of shares, pre-funded warrants, and additional warrants. The investment aims to contribute to Leap's ongoing therapeutic programs while leveraging Winklevoss Capital's expertise in digital assets. This partnership also includes the expansion of Leap's Board of Directors to include nominees from Winklevoss Capital.
Read more →CYPHLeap Therapeutics Announces $58.88 Million Private Placement in Cash Commitments Led by Winklevoss Capital to Initiate a Digital Asset Treasury Strategy Cambridge, MA
Leap Therapeutics announced a private placement of $58.88 million, primarily financed by Winklevoss Capital, to initiate a digital asset treasury strategy. The funding will support both the development of its therapeutic programs and participation in digital assets, with an aim to enhance shareholder value. The investment comes during a period of heightened scrutiny and volatility in the digital asset market, which presents potential risks for the company. The closing of the placement is expected around October 8, 2025, subject to customary conditions.
Read more →CYPHLeap Therapeutics Reports Second Quarter 2025 Financial Results Cambridge, MA
Leap Therapeutics reported its financial results for the second quarter of 2025, showing a net loss of $16.6 million, a reduction from $20.4 million in the same quarter of 2024. The company is restructuring to prioritize corporate development, which resulted in a 75% reduction in workforce. Leap is also exploring strategic alternatives to enhance shareholder value while continuing to focus on its lead candidates sirexatamab and FL-501. The ongoing DeFianCe study and its outcomes may play a crucial role in shaping the company's future direction.
Read more →CYPHLeap Therapeutics Reports Updated Clinical Data from Sirexatamab Colorectal Cancer Study and Announces Exploration of Strategic Alternatives Updated data from DeFianCe study continue to demonstrate statistically signific
Leap Therapeutics reported updated clinical data from its DeFianCe study of sirexatamab in colorectal cancer, indicating statistically significant improvements in certain patient subgroups. The company announced its intention to explore strategic alternatives, including potential partnerships or sales of its product candidates, in response to its financial situation. Additionally, Leap will implement a significant workforce reduction to conserve cash as it winds down the study amid challenging market conditions.
Read more →CYPHLeap Therapeutics Reports First Quarter 2025 Financial Results Cambridge, MA
Leap Therapeutics, a biotechnology company, reported its financial results for the first quarter of 2025, highlighting the progress of its lead candidate, sirexatamab, in clinical trials for colorectal cancer. The company documented a net loss of $15.4 million, reflecting increased research and development costs, particularly from expanded clinical trial activities. Despite the financial losses, there is optimism surrounding the efficacy data showing higher overall response rates and prolonged progression-free survival in specific patient groups. Leap is strategically positioning its resources amidst challenging market conditions as it continues to focus on advancing its therapeutic candidates.
Read more →CYPHLeap Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results Leap to host a conference call to present updated CRC clinical data today
Leap Therapeutics announced its financial results for Q4 and the full year 2024, indicating a reduced net loss of $67.6 million compared to $81.4 million in 2023. The company highlighted advancements in their anti-DKK1 antibody, sirexatamab, particularly noting positive outcomes from the DeFianCe study with the potential for a registrational study. Leap intends to explore further development opportunities for sirexatamab, which targets colorectal cancer patients, as well as its financial strategy for future growth.
Read more →CYPHLeap Therapeutics Reports Initial Clinical Data from Part B of the DeFianCe Study and Part C of the DisTinGuish Study 35% objective response rate (ORR) in second-line colorectal cancer (CRC) patients treated with sirexat
Leap Therapeutics has reported promising initial clinical data from Part B of the DeFianCe study, showing a 35% objective response rate in second-line colorectal cancer patients treated with sirexatamab, bevacizumab, and chemotherapy. The results suggest that this combination therapy outperforms the current standard of care. However, Part C of the DisTinGuish study did not generate a clear positive signal for gastric cancer, leading to a decision to halt plans for further Phase 3 studies in that area. Leap is now preparing for a registrational Phase 3 study for colorectal cancer patients.
Read more →CYPHLeap Therapeutics Reports Third Quarter 2024 Financial Results Cambridge, MA
Leap Therapeutics reported its financial results for Q3 2024, highlighting significant advancements in its oncology pipeline. The company completed enrollment in the expanded Part B of the Phase 2 DeFianCe study for DKN-01 in advanced colorectal cancer. Concurrently, Leap announced the promising preclinical data prompting development of FL-501. However, net losses increased, attributed to rising research and development expenses. Despite these losses, Leap maintains a strong cash position projected to sustain its operations well into 2026.
Read more →CYPHLeap Therapeutics Announces Completion of Enrollment in Part B of the DeFianCe Study of DKN-01 for the Treatment of Colorectal Cancer Patients Cambridge, MA
Leap Therapeutics announced the completion of enrollment of 188 patients in Part B of the DeFianCe study, which evaluates the efficacy of DKN-01 combined with standard of care for advanced colorectal cancer. The study aims to provide data on progression-free survival and is based on encouraging responses from Part A. Initial data from Part B, particularly regarding left-sided CRC patients, is expected in mid-2025. This development underscores the ongoing commitment to advancing treatment options for colorectal cancer.
Read more →CYPHLeap Therapeutics Reports Second Quarter 2024 Financial Results Cambridge, MA
Leap Therapeutics, Inc. has reported its financial results for the second quarter of 2024, noting an increase in the overall response rate to 33% in its ongoing clinical trials for DKN-01. The company successfully completed a $40 million private placement to support the development of its targeted therapies, with plans to expand a key study to 180 patients. However, the company also reported a significant net loss of $20.4 million for the quarter, primarily driven by higher research and development costs. Patient follow-up is underway in additional studies, with data anticipated in the coming quarters.
Read more →CYPHLeap Therapeutics Reports First Quarter 2024 Financial Results Cambridge, MA
Leap Therapeutics reported its financial results for the first quarter of 2024, highlighting a successful $40 million private placement financing. The company presented positive clinical data for its DKN-01 therapy in colorectal cancer and expanded patient enrollment in its studies. Despite a net loss of $13.8 million for the quarter, this was a significant decrease compared to the previous year. The funding and progress in clinical trials have bolstered Leap's prospects, with cash reserves extended into the second quarter of 2026.
Read more →CYPHLeap Therapeutics Announces $40 Million Private Placement Net proceeds, along with existing cash, cash equivalents, and marketable securities are expected to extend cash runway into Q2 2026 and enable expansion of DKN-01
Leap Therapeutics has announced a successful private placement raising $40 million, which will extend its cash runway until Q2 2026. The funding will enable the expansion of the DKN-01 clinical trial, benefiting its potential applications in cancer treatment. The private placement is set to close on April 15, 2024, and involves several institutional investors. Leap's continued development efforts include key studies in colorectal and gastric cancers, leveraging its lead monoclonal antibody program.
Read more →CYPHLeap Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results Cambridge, MA
Leap Therapeutics, Inc. reported its financial results for the fourth quarter and full year 2023, highlighting advancements in its cancer therapeutics pipeline. The company announced a promising 30% overall response rate from its DKN-01 study, with enrollment for additional studies progressing well. Despite the positive developments, the company experienced a net loss of $81.4 million for the year, largely due to increased expenses in research and development and administrative costs. Looking ahead, Leap remains committed to delivering personalized cancer therapies and expanding its clinical trials.
Read more →CYPHcompany presentation
Cypher Genomics presented its corporate strategy and advancements in cancer treatments at a recent conference. The focus was on DKN-01, an innovative therapy demonstrating effectiveness against tumors expressing the DKK1 protein. Preliminary clinical data suggests promising outcomes, especially for patients with high DKK1 levels. The presentations outlined not only the mechanism of action but also potential challenges in broader patient accessibility and the competitive landscape in oncology.
Read more →CYPHLeap Therapeutics to Present New Clinical Data from Part A of DeFianCe Study at the 2024 ASCO Gastrointestinal Cancers Symposium 30% ORR and 93% DCR across heterogenous second-line CRC patients treated with DKN-01 plus b
Leap Therapeutics announced new clinical data from Part A of the DeFianCe study, showing a 30% overall response rate (ORR) and a 93% disease control rate (DCR) in the treatment of second-line advanced colorectal cancer patients with DKN-01 plus bevacizumab and chemotherapy. The results are particularly encouraging for patients with left-sided tumors, with a reported 46% ORR and a 9.4 month preliminary median progression-free survival. The company plans to present these findings at the 2024 ASCO Gastrointestinal Cancers Symposium, and will hold a conference call on January 23, 2024 to discuss further details and data analyses.
Read more →CYPHLeap Therapeutics Reports Third Quarter 2023 Financial Results Cambridge, MA
Leap Therapeutics, Inc. reported third quarter financial results for 2023, showcasing advancements in clinical trials for DKN-01, particularly in the colorectal cancer study. The company has successfully moved to Part B of the DeFianCe study after achieving a favorable response rate in Part A. Financially, Leap recorded a net loss of $13.7 million for the quarter, slightly improved from the previous year, while maintaining a robust cash position of $80.7 million. The ongoing focus remains on executing pivotal studies, showcasing promising developments in the field of immuno-oncology.
Read more →CYPHLeap Therapeutics Reports Second Quarter 2023 Financial Results Cambridge, MA
Leap Therapeutics reported its financial results for Q2 2023, highlighting significant advancements in its DKN-01 program and ongoing trials. The company confirmed an overall response rate exceeding 20%, prompting the initiation of Part B of the DeFianCe study. Additionally, they presented encouraging long-term survival data, with a median overall survival of 19.5 months. However, the report also noted a net loss of $13.4 million, reflecting challenges in balancing R&D expenditures.
Read more →CYPHLeap Therapeutics Announces Initiation of Randomized Controlled Part B of the DeFianCe Study of DKN-01 in Colorectal Cancer Patients Cambridge, MA
Leap Therapeutics has launched Part B of its DeFianCe study for DKN-01, targeting colorectal cancer. The randomized controlled trial will include 130 patients and is motivated by promising early data from Part A. The study aims to measure progression-free survival and overall response rates, with results expected in late 2024. DKN-01 is being evaluated as a second-line treatment in combination with standard care.
Read more →CYPHLeap Therapeutics Announces Reverse Stock Split Cambridge, MA
Leap Therapeutics, Inc. announced a 10-for-1 reverse stock split of its common stock, effective June 20, 2023, at 5 PM ET. This action is designed to increase the per share trading price to comply with Nasdaq's minimum listing requirements while decreasing the total shares outstanding. The reverse split was approved by shareholders during the Annual Meeting held on June 16, 2023. The company's common stock will continue trading under the symbol LPTX following the split.
Read more →CYPHLeap Therapeutics to Present Updated Data from Part A of the DisTinGuish Study of DKN-01 Plus Tislelizumab and Chemotherapy in Gastric Cancer Patients at the 2023 ASCO Annual Meeting 19.5 months median OS in the overall
Leap Therapeutics plans to present updated data from the DisTinGuish study at the 2023 ASCO Annual Meeting, focusing on DKN-01 plus Tislelizumab and chemotherapy for advanced gastric cancer. The study demonstrates encouraging median overall survival of 19.5 months and high response rates for both DKK1-high and PD-L1 low patients. This presentation marks significant progress in developing effective treatment options for this challenging patient population. Key findings highlight potential benefits in survival and quality of life for patients receiving this combination therapy.
Read more →CYPHLeap Therapeutics Reports First Quarter 2023 Financial Results Cambridge, MA
Leap Therapeutics, Inc. has reported its first-quarter financial results for 2023, highlighting advancements in its DKN-01 program. The company completed enrollment in critical stages of its clinical studies and anticipates sharing significant data at the upcoming ASCO conference. However, Leap also reported a much larger net loss this quarter compared to the same period last year, largely linked to the costs associated with acquiring Flame Biosciences. Despite the financial setbacks, the firm's acquisition has positioned it strongly for future developments in cancer therapies.
Read more →CYPHLeap Therapeutics to Present Updated Data from Part A of the DisTinGuish Study of DKN-01 Plus Tislelizumab and Chemotherapy in Gastric Cancer Patients at the 2023 ASCO Annual Meeting Cambridge, MA
Leap Therapeutics is set to present updated long-term follow-up data from Part A of the DisTinGuish study at the 2023 ASCO Annual Meeting. This Phase 2 trial evaluates DKN-01 in conjunction with tislelizumab and chemotherapy for patients with advanced gastroesophageal adenocarcinoma. The presentation will provide insights into the efficacy of this therapeutic combination as a first-line treatment option. The ASCO Annual Meeting takes place from June 2-6, 2023, and will present findings from various parts of the study across multiple countries.
Read more →CYPHLeap Therapeutics Announces Completion of Enrollment in Part A of the DeFianCe Study of DKN-01 for the Treatment of Colorectal Cancer Patients Cambridge, MA
Leap Therapeutics has announced the completion of enrollment for Part A of the Phase 2 DeFianCe study, evaluating DKN-01 in patients with advanced colorectal cancer. This study aims to assess the efficacy of DKN-01, combined with bevacizumab and chemotherapy. The enthusiasm from investigators and participants reflects the urgent medical need in this field. Initial results from the study are expected by mid-2023, marking a critical step in the development of this treatment.
Read more →CYPHLeap Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results Cambridge, MA
Leap Therapeutics reported its financial results for Q4 and full year 2022, highlighting advancements in its pipeline including DKN-01 in gastric cancer trials and the acquisition of Flame Biosciences. The company noted a net loss increase to $54.6 million for the year driven mainly by rising R&D costs. Despite financial losses, Leap aims to generate new data and explore partnerships for its therapeutic programs, positioning itself for future growth in the oncology space.
Read more →CYPHLeap Therapeutics Provides Update on BeiGene Option Agreement for DKN-01 DisTinGuish Trial of DKN-01 plus tislelizumab and chemotherapy to continue as a clinical collaboration Cambridge, MA
Leap Therapeutics has provided an update regarding its collaboration with BeiGene, stating that the option for DKN-01's rights in certain Asian territories has expired. Despite this, both companies will proceed with the Part C of the DisTinGuish trial, which assesses DKN-01 in combination with tislelizumab and chemotherapy for gastric cancer. Enrollment in the trial is set to conclude by late 2023. Leap is focused on generating clinical data and exploring new partnerships while managing a cash runway extended through mid-2025 due to a recent acquisition.
Read more →CYPHLeap Therapeutics Acquires Flame Biosciences Adds FL-301, clinical stage anti-Claudin18.2 antibody, and two preclinical antibody programs to Leap's pipeline Combined cash balance of approximately $115 million enhances ru
Leap Therapeutics has announced the acquisition of Flame Biosciences, gaining FL-301, a clinical stage anti-Claudin18.2 monoclonal antibody, and two preclinical antibody programs. The merger is expected to enhance Leap's pipeline with a combined cash balance of approximately $115 million, funding their developmental activities through mid-2025. As part of the merger, Leap will continue its focus on its existing cancer therapies, including DKN-01. The acquisition is seen as a strategic move to better target biomarker-driven therapies for cancer treatment.
Read more →CYPHLeap Therapeutics Reports Third Quarter 2022 Financial Results
Leap Therapeutics Reports Third Quarter 2022 Mass., November 14, 2022 - Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported financial results for the third quarter ended September 30, 202
Read more →CYPHLeap Therapeutics to Present Updated Data from the DisTinGuish Study of DKN-01 Plus Tislelizumab and Preclinical Data in Colorectal Cancer Models at the SITC Annual Meeting 55% ORR, 73% DCR, and 7.7 month PFS in DKK1-hig
Leap Therapeutics to Present Updated Data from the DisTinGuish Study of DKN-01 Plus Tislelizumab and Preclinical Data in Colorectal Cancer Models at the SITC Annual Meeting 55% ORR, 73% DCR, and 7.7 month PFS in DKK1-high/PD-L1-high second-line gastric cancer patients DKN-0
Read more →CYPHLeap Therapeutics Announces Appointment of Richard L. Schilsky, MD to its Board of Directors Cambridge, MA
Leap Therapeutics Announces Appointment of Richard L. Schilsky, MD to its Board of Directors Cambridge, MA - September 6, 2022 - Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced the
Read more →CYPHLeap Therapeutics Reports Second Quarter 2022 Financial Results
Leap Therapeutics Reports Second Quarter 2022 Mass., August 12, 2022 - Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported financial results for the second quarter ended June 30, 2022. "
Read more →CYPHcompany presentation LEAP THERAPEUTICS DKN - 01 R&D Day
company presentation LEAP THERAPEUTICS DKN - 01 R&D Day July 12, 2022 Forward looking statements 2 This presentation contains forward - looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in th
Read more →CYPHLeap Therapeutics Reports First Quarter 2022
Leap Therapeutics Reports First Quarter 2022 CAMBRIDGE, Mass., May 13, 2022 - Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported financial results for the first quarter ended March 31,
Read more →CYPHLeap Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results Cambridge, MA
Leap Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results MA - March 11, 2022 - Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported financial results for the fourth q
Read more →CYPHLeap Therapeutics to Present Positive New Data from the DisTinGuish Study of DKN-01 Plus Tislelizumab at the ASCO GI Cancers Symposium - DKN-01 plus tislelizumab demonstrated encouraging clinical activity in both first-
Leap Therapeutics to Present Positive New Data from the DisTinGuish Study of DKN-01 Plus Tislelizumab at the ASCO GI Cancers - DKN-01 plus tislelizumab demonstrated encouraging clinical activity in both first- and second-line advanced gastric or gastroesophageal junction cance
Read more →CYPHLeap Therapeutics Reports Third Quarter 2021 Financial Results Cambridge, MA
Leap Therapeutics Reports Third Quarter 2021 Cambridge, MA - November 12, 2021 - Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported financial results for the third quarter ended Septemb
Read more →CYPHLeap Therapeutics Announces Closing of Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of Underwriters' Option to Purchase Additional Shares Cambridge, MA
Leap Therapeutics Announces Closing of Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of Underwriters' Option to Purchase Additional Shares MA - September 24, 2021 - Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developin
Read more →CYPHLeap Therapeutics Announces Pricing of $90 million of Common Stock and Pre-Funded Warrants Cambridge, MA
Leap Therapeutics Announces Pricing of $90 million of Common Stock and Pre-Funded Warrants Cambridge, MA - September 22, 2021 - Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced the
Read more →CYPHLeap Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants Cambridge, MA
Leap Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants Cambridge, MA - September 21, 2021 - Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced th
Read more →CYPHLeap Therapeutics Presents Updated Positive Data from the DisTinGuish Study of DKN-01 Plus Tislelizumab at the ESMO Congress - DKN-01 plus tislelizumab and chemotherapy demonstrated compelling activity in first-line pati
Leap Therapeutics Presents Updated Positive Data from the DisTinGuish Study of DKN-01 Plus Tislelizumab at the ESMO Congress - DKN-01 plus tislelizumab and chemotherapy demonstrated compelling activity in first-line patients with gastric or gastroesophageal junction cancer - A
Read more →CYPHLeap Therapeutics to Present New Data from the DisTinGuish Study of DKN-01 Plus Tislelizumab at the ESMO 2021 Congress - DKN-01 plus tislelizumab and chemotherapy demonstrated compelling activity in first-line patients w
Leap Therapeutics to Present New Data from the DisTinGuish Study of DKN-01 Plus Tislelizumab at the ESMO 2021 Congress plus tislelizumab and chemotherapy demonstrated compelling activity in first-line patients with gastric or gastroesophageal junction cancer patients who rec
Read more →CYPHLeap Therapeutics Reports Second Quarter 2021 Financial Results and Upcoming Data Presentation Cambridge, MA
Leap Therapeutics Reports Second Quarter 2021 Financial Results and Upcoming Data Presentation Cambridge, MA - August 13, 2021 - Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported fina
Read more →CYPHLeap Therapeutics Reports First Quarter 2021 Financial Results Cambridge, MA
Leap Therapeutics Reports First Quarter 2021 Cambridge, MA - May 14, 2021 - Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported financial results for the first quarter ended March 31, 20
Read more →CYPHLeap Therapeutics Announces Completion of Enrollment for First-Line Patient Cohort in Study of DKN-01 in Combination with Tislelizumab for the Treatment of Gastric or Gastroesophageal Junction Cancer Cambridge, MA
Leap Therapeutics Announces Completion of Enrollment for First-Line Patient Cohort in Study of DKN-01 in Combination with Tislelizumab for the Treatment of Gastric or Gastroesophageal Cambridge, MA - April 1, 2021 - Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology comp
Read more →CYPHLeap Therapeutics Presents DKN-01 Clinical Data at the Society of Gynecologic Oncology 2021 Annual Meeting on Women's Cancer DKN-01 Monotherapy Demonstrated Clinical Activity in Patients with Endometrial Cancer Tumoral D
Leap Therapeutics Presents DKN-01 Clinical Data at the Society of Gynecologic Oncology 2021 Annual Meeting on Women's Cambridge, MA - March 22, 2021 - Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeuti
Read more →CYPHLeap Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results Cambridge, MA
Leap Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results MA - March 12, 2021 - Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported financial results for the fourth q
Read more →CYPHLeap Therapeutics Reports Third Quarter 2020 Financial Results Cambridge, MA
Leap Therapeutics Reports Third Quarter 2020 Financial Results Cambridge, MA - November 12, 2020 - Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported financial results for the third qu
Read more →CYPHLeap Therapeutics Presents Updated Data for DKN-01 in Esophagogastric Cancer Patients at SITC 2020 35 th Annual Meeting High Levels of Tumoral DKK1 Expression Correlated with Improved Clinical Outcomes in Heterogenous Es
Leap Therapeutics Presents Updated Data for DKN-01 in Esophagogastric Cancer Patients at SITC 2020 35th Annual Meeting High Levels of Tumoral DKK1 Expression Correlated with Improved Clinical Outcomes in Heterogenous Esophagogastric Cancer Patients Treated with DKN-01 as a M
Read more →CYPHLeap Therapeutics Announces FDA Fast Track Designation Granted to DKN-01 for the Treatment of Gastric and Gastroesophageal Junction Cancer Cambridge, MA
Leap Therapeutics Announces FDA Fast Track Designation Granted to DKN-01 for the Treatment of Gastric and Gastroesophageal Cambridge, MA - September 24, 2020 - Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology t
Read more →CYPHLeap Therapeutics and BeiGene Announce First Patient Dosed in Study of DKN-01 in Combination with Tislelizumab for the Treatment of Metastatic Gastric or Gastroesophageal Junction Cancer Cambridge, MA and Beijing, China
Exhibit 99.1 Leap Therapeutics and BeiGene Announce First Patient Dosed in Study of DKN-01 in Combination with Tislelizumab for the Treatment of Metastatic Gastric or Gastroesophageal Junction Cancer Cambridge, MA and Beijing, China - September 21, 2020 - Leap Therapeutics, Inc
Read more →CYPHLeap Therapeutics Reports Second Quarter 2020 Financial Results Cambridge, MA
Leap Therapeutics Reports Second Quarter 2020 Financial Results Cambridge, MA - August 13, 2020 - Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported financial results for the second qu
Read more →CYPHLeap Therapeutics Announces Full Exercise of Underwriters' Option to Purchase Additional Shares Cambridge, MA
Leap Therapeutics Announces Full Exercise of Underwriters' Option to Purchase Additional Shares Cambridge, MA - June 25, 2020 - Leap Therapeutics, Inc. (NASDAQ:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced the
Read more →CYPHLeap Therapeutics Announces Closing of Public Offering of Common Stock and Pre-Funded Warrants Cambridge, MA
Leap Therapeutics Announces Closing of Public Offering of Common Stock and Pre-Funded Warrants Cambridge, MA - June 22, 2020 - Leap Therapeutics, Inc. (NASDAQ:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced the c
Read more →CYPHLeap Therapeutics Announces Pricing of $45 million of Common Stock and Pre-Funded Warrants Cambridge, MA
Leap Therapeutics Announces Pricing of $45 million of Common Stock and Pre-Funded Warrants June 18, 2020 - Leap Therapeutics, Inc. (NASDAQ:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced the pricing of an underwri
Read more →CYPHLeap Therapeutics Announces Oprhan Drug Designation of DKN-01 for the Treatment of Gastric and Gastroesophageal Junction Cancer Cambridge, MA
Leap Therapeutics Announces Oprhan Drug Designation of DKN-01 for the Treatment of Gastric and Gastroesophageal Cambridge, MA - June 11, 2020 - Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, tod
Read more →CYPHLeap Therapeutics Reports First Quarter 2020 Financial Results Cambridge, MA
Leap Therapeutics Reports First Quarter 2020 Financial Results Cambridge, MA - May 14, 2020 - Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported financial results for the first quarter
Read more →CYPHLeap Therapeutics to Present Updated Data for DKN-01 Monotherapy and Paclitaxel Combination In Gynecologic Cancers Enhanced Survival Outcomes Achieved in Patients with Wnt Activating Mutations and DKK1-high Tumors DKN-01
Leap Therapeutics to Present Updated Data for DKN-01 Monotherapy and Paclitaxel Combination In Gynecologic Cancers Enhanced Survival Outcomes Achieved in Patients with Wnt Activating Mutations and DKK1-high Tumors DKN-01 Monotherapy Treated Endometrial Cancer Patient Maintain
Read more →CYPHLeap Therapeutics Announces Executive Leadership Changes Cambridge, MA
Leap Therapeutics Announces Executive Cambridge, MA - March 18, 2020 - Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced changes to the Company's Executive Leadership Team. All change
Read more →CYPHLeap Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results Cambridge, MA
Leap Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results Cambridge, MA - March 16, 2020 - Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported financial results for
Read more →CYPHLeap Therapeutics Announces Closing of Previously Announced Equity Financing Cambridge, MA
Leap Therapeutics Announces Closing of Previously Announced Equity Financing Cambridge, MA - January 7, 2020 - Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced the closing of its pr
Read more →CYPHLeap Therapeutics and BeiGene Announce Exclusive Option and License Agreement for DKN-01 and Leap Announces $27 Million Equity Financing BeiGene granted option to develop and commercialize Leap's DKN-01 in the Asia Pacif
Leap Therapeutics and BeiGene Announce Exclusive Option and License Agreement for DKN-01 and Leap Announces $27 Million Equity Cambridge, MA and Beijing, China- January 3, 2020 - Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company developing targeted immuno-oncolog
Read more →CYPHLeap Therapeutics Reports Third Quarter 2019 Financial Results DKN-01 data continues to show robust activity, including a monotherapy complete response, in cancer patients with high DKK-1 expression and Wnt signaling alt
Leap Therapeutics Reports Third Quarter 2019 Financial Results DKN-01 data continues to show robust activity, including a monotherapy complete response, in cancer patients with high DKK-1 expression and Wnt signaling alterations De-prioritizing further development in TRX518 to
Read more →CYPHLeap Therapeutics to Present Updated Data for DKN-01 Monotherapy and Paclitaxel Combination at the 2019 International Gynecologic Cancer Society Annual Global Meeting DKN-01 Monotherapy Patient with an Ongoing Complete R
Leap Therapeutics to Present Updated Data for DKN-01 Monotherapy and Paclitaxel Combination at the 2019 International Gynecologic Cancer Society Annual Global Meeting DKN-01 Monotherapy Patient with an Ongoing Complete Response Enhanced PFS in patients with Wnt Activating Muta
Read more →CYPHLeap Therapeutics Reports Second Quarter 2019 Financial Results Positive data from DKN-01 plus KEYTRUDA (pembrolizumab) combination study First patients enrolled in TRX518 plus BAVENCIO (avelumab) and cyclophoshamide com
Leap Therapeutics Reports Second Quarter 2019 Financial Results Positive data from DKN-01 plus KEYTRUDA (pembrolizumab) combination study First patients enrolled in TRX518 plus BAVENCIO (avelumab) and cyclophoshamide combination study Cambridge, MA August 9, 2019 Leap Therapeu
Read more →CYPHLeap Presents Positive Clinical Results for the Combination of DKN-01 plus Keytruda and Provides DKN-01 Program Update Enhanced survival outcomes in DKK1-high gastroesophageal junction and gastric cancer patients DKK1-hi
Leap Presents Positive Clinical Results for the Combination of DKN-01 plus Keytruda and Provides DKN-01 Program Update Enhanced survival outcomes in DKK1-high gastroesophageal junction and gastric cancer patients DKK1-high biomarker enables future patient selection Live conf
Read more →CYPHLeap Therapeutics Announces Common Stock Purchase Agreements For Up to $21 Million with Lincoln Park Capital Cambridge, MA
Leap Therapeutics Announces Common Stock Purchase Agreements For Up to $21 Million with Lincoln Park Capital Cambridge, MA July 11, 2019 Leap Therapeutics, Inc. (NASDAQ:LPTX), a biotechnology company developing targeted and immuno-oncology therapeutics, today announced it has e
Read more →CYPHLeap Therapeutics Reports First Quarter 2019 Financial Results Strong clinical trial enrollment leading to significant 2019 data First patient enrolled in DKN-01 prostate cancer study Cambridge, MA
Leap Therapeutics Reports First Quarter 2019 Financial Results Strong clinical trial enrollment leading to significant 2019 data First patient enrolled in DKN-01 prostate cancer study Cambridge, MA May 15, 2019 Leap Therapeutics, Inc. (NASDAQ:LPTX), a biotechnology company dev
Read more →CYPHLeap Therapeutics Reports Clinical Update and 2018 Financial Results Cambridge, MA
Leap Therapeutics Reports Clinical Update and 2018 Financial Results Cambridge, MA April 1, 2019 Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company developing targeted and immuno-oncology therapeutics, today reported an update on its clinical development programs al
Read more →CYPHLeap Therapeutics Presents at Society of Gynecologic Oncology 50 th Annual Meeting on Women s Cancer DKN-01 Monotherapy and Combination Partial Responses in heavily pre-treated patients Enhanced benefit in patients with
Leap Therapeutics Presents at Society of Gynecologic Oncology 50th Annual Meeting on Women s Cancer DKN-01 Monotherapy and Combination Partial Responses in heavily pre-treated patients Enhanced benefit in patients with Wnt Pathway Alterations Cambridge, MA March 18, 2019 Leap
Read more →CYPHLeap Therapeutics Announces Closing of Public Offering and Full Exercise of Underwriters Option to Purchase Additional Securities Cambridge, MA
Leap Therapeutics Announces Closing of Public Offering and Full Exercise of Underwriters Option to Purchase Additional Securities Cambridge, MA February 5, 2019 Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology ther
Read more →CYPHLeap Therapeutics Announces Pricing of $11.5 Million Public Offering of Common Stock and Warrants Cambridge, MA
Leap Therapeutics Announces Pricing of $11.5 Million Public Offering of Common Stock and Warrants Cambridge, MA February 1, 2019 Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced the pr
Read more →CYPHLeap Therapeutics Announces Proposed Public Offering of Common Stock and Warrants Cambridge, MA
Leap Therapeutics Announces Proposed Public Offering of Common Stock and Warrants Cambridge, MA January 31, 2019 Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that it has commenced
Read more →CYPHLeap Therapeutics Announces an Investigator-Initiated Study of DKN-01 in Patients with DKK1+ Advanced Prostate Cancer Cambridge, MA
Leap Therapeutics Announces an Investigator-Initiated Study of DKN-01 in Patients with DKK1+ Advanced Prostate Cancer Cambridge, MA January 14, 2019 Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company developing targeted and immuno-oncology therapeutics, today announ
Read more →CYPHLeap Therapeutics Presents TRX518 Data at ESMO Immuno-Oncology Congress 2018 and Updated Data from DKN-01 Study in Biliary Tract Cancer TRX518 (GITR Agonist) Clinical Perspectives conference call and webcast on Monday, D
Leap Therapeutics Presents TRX518 Data at ESMO Immuno-Oncology Congress 2018 and Updated Data from DKN-01 Study in Biliary Tract Cancer TRX518 (GITR Agonist) Clinical Perspectives conference call and webcast on Monday, December 17 at 8:30 AM ET Cambridge, MA December 14, 2018
Read more →CYPHLeap Therapeutics Reports Third Quarter 2018 Business Update and Financial Results Cambridge, MA
Leap Therapeutics Reports Third Quarter 2018 Business Update and Financial Results Cambridge, MA November 9, 2018 Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company developing targeted and immuno-oncology therapeutics, today reported a business update and financial
Read more →CYPHLeap Therapeutics Presents Esophagogastric Cancer Data at ESMO 2018 Annual Congress Live conference call and webcast on Monday, October 22 at 8:00 AM ET Cambridge, MA
Leap Therapeutics Presents Esophagogastric Cancer Data at ESMO 2018 Annual Congress Live conference call and webcast on Monday, October 22 at 8:00 AM ET Cambridge, MA October 21, 2018 Leap Therapeutics, Inc. (NASDAQ:LPTX) today presented clinical data from its ongoing Phase I/
Read more →CYPHLeap Therapeutics Reports Second Quarter 2018 Business Update and Financial Results Cambridge, MA
Leap Therapeutics Reports Second Quarter 2018 Business Update and Financial Results Cambridge, MA August 8, 2018 Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company developing targeted and immuno-oncology therapeutics, today reported a business update and financial r
Read more →CYPHCompany Update July 2018 Forward-Looking This presentation contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in thi
Company Update July 2018 Forward-Looking This presentation contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this presentation, including statements regarding our strategy
Read more →CYPHLeap Therapeutics Reports First Quarter 2018 Financial Results Conference Call with DKN-01 Clinical Investigators Planned for
Leap Therapeutics Reports First Quarter 2018 Financial Results Conference Call with DKN-01 Clinical Investigators Planned for May 18, 2018 Cambridge, MA May 11, 2018 Leap Therapeutics, Inc. (NASDAQ:LPTX), a biotechnology company developing targeted and immuno-oncology therapeut
Read more →CYPHLeap Therapeutics Presents Nonclinical and Clinical Data on DKN-01 at AACR 2018 Annual Meeting Cambridge, MA
Leap Therapeutics Presents Nonclinical and Clinical Data on DKN-01 at AACR 2018 Annual Meeting Cambridge, MA April 16, 2018 Leap Therapeutics, Inc. (NASDAQ:LPTX) today presented nonclinical and clinical data on DKN-01, Leap s anti-DKK1 monoclonal antibody, at the American Assoc
Read more →CYPHLeap Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters Option to Purchase Additional Shares Cambridge, MA
Leap Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters Option to Purchase Additional Shares Cambridge, MA March 27, 2018 Leap Therapeutics, Inc. (NASDAQ:LPTX), a biotechnology company focused on developing targeted and immuno-onc
Read more →CYPHLeap Therapeutics Announces Pricing of $14 Million Public Offering of Common Stock Cambridge, MA
Leap Therapeutics Announces Pricing of $14 Million Public Offering of Common Stock Cambridge, MA March 23, 2018 Leap Therapeutics, Inc. (NASDAQ:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced the pricing of an under
Read more →CYPHLeap Therapeutics Announces Proposed Public Offering of Common Stock Cambridge, MA
Leap Therapeutics Announces Proposed Public Offering of Common Stock Cambridge, MA March 22, 2018 Leap Therapeutics, Inc. (NASDAQ:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that it has commenced an underwritten
Read more →CYPHLeap Therapeutics Leap Therapeutics Provides DKN-01 Program Update and Announces Scientific Presentations at AACR Annual Meeting
Leap Therapeutics Provides DKN-01 Program Update and Announces Scientific Presentations at AACR Annual Meeting CAMBRIDGE, Mass., March 14, 2018 (GLOBE NEWSWIRE) Leap Therapeutics, Inc. (NASDAQ:LPTX), a biotechnology company developing targeted and immuno-oncology therapeutics, t
Read more →CYPHLeap Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results and Announces Date of its Annual Meeting of Stockholders Cambridge, MA
Leap Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results and Announces Date of its Annual Meeting of Stockholders Cambridge, MA February 23, 2018 Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company developing targeted and immuno-oncology therapeut
Read more →CYPHLeap Therapeutics Announces $18 Million Private Placement Offering
Leap Therapeutics Announces $18 Million Private Placement Offering CAMBRIDGE, Mass., Nov. 15, 2017 (GLOBE NEWSWIRE) Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company developing targeted and immuno-oncology therapeutics, today announced it has entered into a purchase
Read more →CYPHLeap Therapeutics Reports Third Quarter 2017 Financial Results and Announces First Patient Dosed with DKN-01 and KEYTRUDA (pembrolizumab) in Esophagogastric Cancer Trial Cambridge, MA
Leap Therapeutics Reports Third Quarter 2017 Financial Results and Announces First Patient Dosed with DKN-01 and KEYTRUDA (pembrolizumab) in Esophagogastric Cancer Trial Cambridge, MA November 13, 2017 Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company developing tar
Read more →CYPHLeap Therapeutics Reports Second Quarter 2017 Financial Results Cambridge, MA
Leap Therapeutics Reports Second Quarter 2017 Financial Results Cambridge, MA August 11, 2017 Leap Therapeutics, Inc. (NASDAQ:LPTX), a biotechnology company developing targeted and immuno-oncology therapeutics, today reported financial results for the second quarter ended June 3
Read more →CYPHLeap Therapeutics Announces Collaboration with Merck to Evaluate KEYTRUDA (pembrolizumab) in Combination with DKN-01 in Esophagogastric Cancer Cambridge, MA
Leap Therapeutics Announces Collaboration with Merck to Evaluate KEYTRUDA (pembrolizumab) in Combination with DKN-01 in Esophagogastric Cancer Cambridge, MA June 21, 2017 Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company developing targeted and immuno-oncology thera
Read more →CYPHLeap Therapeutics Reports First Quarter 2017 Financial Results Company announces investigator-sponsored study of DKN-01 in advanced hepatocellular carcinoma Cambridge, MA
Leap Therapeutics Reports First Quarter 2017 Financial Results Company announces investigator-sponsored study of DKN-01 in advanced hepatocellular carcinoma Cambridge, MA May 12, 2017 Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company developing targeted and immuno-
Read more →CYPHLeap Therapeutics Reports Full Year 2016 Financial Results and Progression-Free Survival Data in Advanced Biliary Tract Cancers Cambridge, MA
Leap Therapeutics Reports Full Year 2016 Financial Results and Progression-Free Survival Data in Advanced Biliary Tract Cancers Cambridge, MA March 31, 2017 Leap Therapeutics, Inc. (Nasdaq: LPTX), a biotechnology company developing targeted and immuno-oncology therapeutics, tod
Read more →Competitive Position
How CYPH ranks across every disease it competes inCompetitive Position is a premium feature
See how CYPH ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial